Skip to main content
SpringerLink
Log in

Cannabinoids and drugs of abuse

  • Chapter
Cannabinoids as Therapeutics

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Atha MJ, Bianchard S (1997) Self-reported drug consumption patterns and attitudes towards drugs among 1333 regular cannabis users. Wigan: Independent Drug Monitoring Unit

    Google Scholar 

  2. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiat 58: 322–328

    Article  PubMed  Google Scholar 

  3. Jones RT (1978) Marihuana: human effects. In: LL Iversen, SD Iversen, SH Snyder (eds): Handbook of Psychopharmacology, vol 12. Plenum Press, New York, 373–412

    Google Scholar 

  4. Jones RT (1987) Drug of abuse profile: cannabis. Clin Chem 33: 72B–81B

    PubMed  Google Scholar 

  5. Hollister LE (1986) Health aspects of cannabis. Pharmacol Rev 38: 1–20

    PubMed  Google Scholar 

  6. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edition) (DSM-IV). Washington, DC: APA

    Google Scholar 

  7. Swift W, Hall W, Teesson M (2001) Cannabis use and dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Addiction 96: 737–748

    Article  PubMed  Google Scholar 

  8. Budney AJ, Hughes JR, Moore BA, Novy PL (2001) Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiat 58: 917–924

    Article  PubMed  Google Scholar 

  9. Maldonado R (2002) Study of cannabinoid dependence in animals. Pharmacol Ther 95: 153–164

    Article  PubMed  Google Scholar 

  10. Tanda G, Goldberg SR (2003) Cannabinoids: reward, dependence, and underlying neurochemical mechanisms — a review of recent preclinical data. Psychopharmacology (Berl) 169: 115–134

    Article  PubMed  Google Scholar 

  11. Magour S, Coper H, Fahndrich C (1977) Is tolerance to delta-9-THC cellular or metabolic? The subcellular distribution of delta-9-tetrahydrocannabinol and its metabolites in brains of tolerant and non-tolerant rats. Psychopharmacology (Berl) 51: 141–145

    Article  PubMed  Google Scholar 

  12. Costa B, Parolaro D, Colleoni M (1996) Chronic cannabinoid, CP-55,940, administration alters biotransformation in the rat. Eur J Pharmacol 313: 17–24

    Article  PubMed  Google Scholar 

  13. Hutcheson DM, Tzavara ET, Smadja C, Valjent E, Roques BP, Hanoune J, Maldonado R. (1998) Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol 125: 1567–1577

    Article  PubMed  Google Scholar 

  14. Rubino T, Viganò D, Massi P, Parolaro D (2000) Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940. J Neurochem 75: 2080–2086

    Article  PubMed  Google Scholar 

  15. Rubino T, Viganò D, Massi P, Spinello M, Zagato E, Giagnoni G, Parolaro D (2000) Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology 39: 1331–1336

    Article  PubMed  Google Scholar 

  16. Lee MC, Smith FL, Stevens DL, Welch SP (2003) The role of several kinases in mice tolerant to delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 305: 593–599

    Article  PubMed  Google Scholar 

  17. Rubino T, Forlani G, Viganò D, Zippel R, Parolaro D (2004) Modulation of extracellular signal-regulated kinases cascade by chronic Delta(9)-tetrahydrocannabinol treatment. Mol Cell Neurosci 25: 355–362

    Article  PubMed  Google Scholar 

  18. Grigorenko E, Kittler J, Clayton C, Wallace D, Zhuang S, Bridges D, Bundey S, Boon A, Pagget C, Hayashizaki S et al. (2002) Assessment of cannabinoid induced gene changes: tolerance and neuroprotection. Chem Phys Lipids 121: 257–266

    Article  PubMed  Google Scholar 

  19. Di Marzo V, Berrendero F, Bisogno T, Gonzalez S, Cavaliere P, Romero J, Cebeira M, Ramos JA, Fernandez-Ruiz JJ (2000) Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. J Neurochem 74: 1627–1635

    Article  PubMed  Google Scholar 

  20. Tzavara ET, Valjent E, Firmo C, Mas M, Beslot F, Defer N, Roques BP, Hanoune J, Maldonado R (2000) Cannabinoid withdrawal is dependent upon PKA activation in the cerebellum. Eur J Neurosci 12: 1038–1046

    Article  PubMed  Google Scholar 

  21. Rodriguez de Fonseca F, Carrera MR, Navarro M, Koob GF, Weiss F (1997) Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276:2050–2054

    Article  PubMed  Google Scholar 

  22. Diana M, Melis M, Muntoni AL, Gessa GL (1998) Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci USA 95: 10269–10273

    Article  PubMed  Google Scholar 

  23. Tanda G, Loddo P, Di Chiara G (1999) Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. Eur J Pharmacol 376: 23–26

    Article  PubMed  Google Scholar 

  24. De Vries TJ, Schoffelmeer AN, Binnekade R, Mulder AH, Vanderschuren LJ (1998) Drug-induced reinstatement of heroin-and cocaine-seeking behaviour following long-term extinction is associated with expression of behavioral sensitization. Eur J Neurosci 10: 3565–3571

    Article  PubMed  Google Scholar 

  25. Cadoni C, Pisanu A, Solinas M, Acquas E, Di Chiara G (2001) Behavioural sensitization after repeated exposure to Delta 9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology 158: 259–266

    Article  PubMed  Google Scholar 

  26. Rubino T, Viganò D, Massi P, Parolaro D (2001) The psychoactive ingredient of marijuana induces behavioral sensitization. Eur J Neurosci 14: 884–886

    Article  PubMed  Google Scholar 

  27. Rubino T, Viganò D, Massi P, Parolaro D (2003) Cellular mechanisms of Delta 9-tetrahydrocannabinol behavioral sensitization. Eur JNeurosci 17: 325–330

    Article  Google Scholar 

  28. Jarbe TU, Johansson JO, Henriksson BG (1976) Characteristics of tetrahydrocannabinol (THC)-produced discrimination in rats. Psychopharmacology 48: 181–187

    Article  PubMed  Google Scholar 

  29. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240–244

    Article  PubMed  Google Scholar 

  30. Mansbach RS, Rovetti CC, Macor JE (1996) CP-135,807, a selective 5-HT1D agonist: effects in drug discrimination and punishment procedures in the pigeon. Psychopharmacology 128: 313–319

    Article  PubMed  Google Scholar 

  31. Perio A, Rinaldi-Carmona M, Maruani J, Barth F, Le Fur G, Soubrie P (1996) Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A. Behav Pharmacol 7:65–71

    PubMed  Google Scholar 

  32. Wiley JL, Martin BR (1999) Effects of SR141716A on diazepam substitution for delta9-tetrahydrocannabinol in rat drug discrimination. Pharmacol Biochem Behav 64: 519–522

    Article  PubMed  Google Scholar 

  33. Wiley JL, Ryan WJ, Razdan RK, Martin BR (1998) Evaluation of cannabimimetic effects of structural analogs of anandamide in rats. Eur J Pharmacol 355: 113–118

    Article  PubMed  Google Scholar 

  34. Jarbe TU, Lamb RJ, Lin S, Makriyannis A (2001) (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology 156: 369–380

    Article  PubMed  Google Scholar 

  35. Wiley JL, Martin BR (1999) Effects of SR141716A on diazepam substitution for delta9-tetrahydrocannabinol in rat drug discrimination. Pharmacol Biochem Behav 64: 519–522

    Article  PubMed  Google Scholar 

  36. Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W (1998) Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience 85: 327–330

    Article  PubMed  Google Scholar 

  37. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, Chowen JA, Gomez R, del Arco I, Villanua MA et al. (2001) Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21: 5344–5350

    PubMed  Google Scholar 

  38. Fattore L, Cossu G, Martellotta CM, Fratta W (2001) Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology 156: 410–416

    Article  PubMed  Google Scholar 

  39. Tanda G, Munzar P, Goldberg SR (2000) Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 3: 1073–1074

    Article  PubMed  Google Scholar 

  40. Justinova Z, Tanda G, Redhi GH, Goldberg SR (2003) Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology 169: 135–140

    Article  PubMed  Google Scholar 

  41. Lepore M, Vorel SR, Lowinson J, Gardner EL (1995) Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. Life Sci 56:2073–2080

    Article  PubMed  Google Scholar 

  42. Valjent E, Maldonado R (2000) A behavioral model to reveal place preference to delta 9-tetrahydrocannabinol in mice. Psychopharmacology 147: 436–438

    Article  Google Scholar 

  43. Parker LA, Gillies T (1995) THC-induced place and taste aversions in Lewis and Sprague-Dawley rats. Behav Neurosci 109: 71–78

    Article  PubMed  Google Scholar 

  44. McGregor IS, Issakidis CN, Prior G (1996) Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacol Biochem Behav 53: 657–664

    Article  PubMed  Google Scholar 

  45. Sanudo-Pena MC, Tsou K, Delay ER, Hohman AG, Force M, Walker JM (1997) Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci Lett 223: 125–128

    Article  PubMed  Google Scholar 

  46. Chaperon F, Soubrie P, Puech AJ, Thiebot MH (1998) Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 135: 324–332

    Article  PubMed  Google Scholar 

  47. Mallet PE, Beninger RJ (1998) Delta9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance. Life Sci 62: 2431–2439

    Article  PubMed  Google Scholar 

  48. Braida D, Pozzi M, Cavallini R, Sala M (2001) Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience 104: 923–926

    Article  PubMed  Google Scholar 

  49. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R (2002) Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 22:1146–1154

    PubMed  Google Scholar 

  50. Cheer JF, Kendall DA, Marsden CA (2000) Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology 151: 25–30

    Article  PubMed  Google Scholar 

  51. Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13: 177–184

    Article  PubMed  Google Scholar 

  52. Maldonado R, Rodriguez de Fonseca F (2002) Cannabinoid addiction: behavioral models and neural correlates. JNeurosci 22: 3326–3331

    Google Scholar 

  53. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA (1999) Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 20: 287–294

    Article  PubMed  Google Scholar 

  54. Castane A, Valjent E, Ledent C, Parmentier M, Maldonado R, Valverde O (2002) Lack of CB1 cannabinoid receptors modifies nicotine behavioral responses, but not nicotine abstinence. Neuropharmacology 43: 857–867

    Article  PubMed  Google Scholar 

  55. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P (2002) SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13: 451–463

    PubMed  Google Scholar 

  56. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2000) Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 12: 4038–4046

    Article  PubMed  Google Scholar 

  57. Rice OV, Gordon N, Gifford AN (2002) Conditioned place preference to morphine in cannabinoid CB1 receptor knockout mice. Brain Res 945: 135–138

    Article  PubMed  Google Scholar 

  58. Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, Parmentier M, Fratta W (2001) Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 118: 61–65

    Article  PubMed  Google Scholar 

  59. Caille S, Parsons LH (2003) SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. Eur JNeurosci 18: 3145–3149

    Article  Google Scholar 

  60. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR (2003) The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 306: 93–102

    Article  PubMed  Google Scholar 

  61. Mechoulam R, Parker L (2003) Cannabis and alcohol — a close friendship. Trends Pharmacol Sci 24: 266–268

    Article  PubMed  Google Scholar 

  62. Poncelet M, Maruani J, Calassi R, Soubrie P (2003) Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci Lett 343: 216–218

    PubMed  Google Scholar 

  63. Hungund BL, Szakall I, Adam A, Basavarajappa BS, Vadasz C (2003) Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem 84: 698–704

    Article  PubMed  Google Scholar 

  64. Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G (2003) Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci USA 100: 1393–1398

    Article  PubMed  Google Scholar 

  65. Braida D, Sala M (2002) Role of the endocannabinoid system in MDMA intracerebral self-administration in rats. Br J Pharmacol 136: 1089–1092

    Article  PubMed  Google Scholar 

  66. Fattore L, Spano MS, Cossu G, Deiana S, Fratta W (2003) Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci 17: 1723–1726

    Article  PubMed  Google Scholar 

  67. De Vries TJ, Homberg JR, Binnekade R, Raaso H, Schoffelmeer AN (2003) Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berl) 168: 164–169

    Article  PubMed  Google Scholar 

  68. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, Vanderschuren LJ, Schoffelmeer AN (2001) A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7:1151–1154

    Article  PubMed  Google Scholar 

  69. Serra S, Brunetti G, Pani M, Vacca G, Carai MA, Gessa GL, Colombo G (2002) Blockade by the cannabinoid CB(1) receptor antagonist, SR 141716, of alcohol deprivation effect in alcohol-preferring rats. Eur J Pharmacol 443: 95–97

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center of Neuroscience, University of Insubria, Via A. da Giussano 10, 20152, Busto Arsizio (VA), Italy

    Daniela Parolaro & Tiziana Rubino

Authors
  1. Daniela Parolaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tiziana Rubino
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Faculty, Hebrew University, Ein Kerem, Jerusalem, 91010, Israel

    Raphael Mechoulam

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Parolaro, D., Rubino, T. (2005). Cannabinoids and drugs of abuse. In: Mechoulam, R. (eds) Cannabinoids as Therapeutics. Milestones in Drug Therapy MDT. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7358-X_12

Download citation

Publish with us

Policies and ethics

Search

Navigation